Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Esophagus
Published in: Esophagus 1/2019

Open Access 01-01-2019 | Special Article

Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2

Authors: Yuko Kitagawa, Takashi Uno, Tsuneo Oyama, Ken Kato, Hiroyuki Kato, Hirofumi Kawakubo, Osamu Kawamura, Motoyasu Kusano, Hiroyuki Kuwano, Hiroya Takeuchi, Yasushi Toh, Yuichiro Doki, Yoshio Naomoto, Kenji Nemoto, Eisuke Booka, Hisahiro Matsubara, Tatsuya Miyazaki, Manabu Muto, Akio Yanagisawa, Masahiro Yoshida

Published in: Esophagus | Issue 1/2019

Login to get access

Excerpt

Endoscopic resection (ER) includes endoscopic mucosal resection (EMR), wherein the affected mucosal lesion is held or aspirated and resected with a snare, and endoscopic submucosal dissection (ESD), which refers to en bloc resection of an extensive lesion using an IT knife or hook knife [1‐4]. Other endoscopic treatments available include photodynamic therapy (PDT), argon plasma coagulation (APC), and electromagnetic coagulation therapy. …
Literature
1.
Oyama T, Tomori A, Hotta K, et al. Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol. 2005;3:S67–70.PubMed
2.
Fujishiro M, Yahagi N, Kakushima N, et al. Endoscopic submucosal dissection of esophageal squamous cell neoplasms. Clin Gastroenterol Hepatol. 2006;4:688–94.PubMed
3.
Ishihara R, Iishi H, Uedo N, et al. Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. Gastrointest Endosc. 2008;68:1066–72.PubMed
4.
Takahashi H, Arimura Y, Masao H, et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc. 2010;72:255–64.PubMed
5.
Katada C, Muto M, Momma K, et al. Clinical outcome after endoscopic mucosal resection for esophageal squamous cell carcinoma invading the muscularis mucosae–a multicenter retrospective cohort study. Endoscopy. 2007;39:779–83.PubMed
6.
Shimizu Y, Tsukagoshi H, Fujita M, et al. Long–term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper. Gastointest Endosc. 2002;56:387–90.
7.
Mizuta H, Nishimori I, Kuratani Y, et al. Predictive factors for esophageal stenosis after endoscopic submucosal dissection for superficial esophageal cancer. Dis Esophagus. 2009;22:626–31.PubMed
8.
Katada C, Muto M, Manabe T, et al. Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc. 2003;57:165–9.PubMed
9.
Yano T, Muto M, Minashi K, et al. Photodynamic therapy as salvage treatment for local failures after definitive chemo–radio therapy for esophageal cancer. Gastrointest Endosc. 2005;62:31–6.PubMed
10.
The Japanese Society for Esophageal Disease. comprehensive registry of esophageal cancer in Japan, 2009. Esophagus. 2016;13:110–37.
11.
Endo M, Yoshino K, Kawano T, et al. Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracis esophagus. Dis Esophagus. 2000;13:125–9.PubMed
12.
Noguchi H, Naomoto Y, Kondo H, et al. Evaluation of endoscopic mucosal resection for superficial esophageal carcinoma. Surg Laparosc Endosc Percutum Tech. 2000;10:343–50.
13.
Araki K, Ohno S, Egashira A, et al. Pathological feature of superficial esophageal squamous cell carcinoma with lymph node and distal metastasis. Cancer. 2002;94:570–5.PubMed
14.
Eguchi T, Nakanishi Y, Shimoda T, et al. Histological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. Modern Pathol. 2006;19:475–80.
15.
Kim DU, Lee JH, Min BH, et al. Risk factors of lymph node metastasis in T1 esophageal squamous cell carcinoma. J Gastro Hepatol. 2008;23:619–25.
16.
Choi JY, Park YS, Jung HY, et al. Feasibility of endoscopic resection in superficial esophageal squamous carcinoma. Gastrointest Endosc. 2011;73:881–9.PubMed
17.
Akutsu Y, Uesato M, Shuto K, et al. The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 patients. Ann Surg. 2013;257:1032–8.PubMed
18.
Tanaka T, Matono S, Mori N, et al. T1 squamous cell carcinoma of the esophagus: long–term outcomes and prognostic factors after esophagectomy. Ann Surg Oncol. 2014;21:932–8.PubMed
19.
Barbour AP, Jones M, Brown I, et al. Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol. 2010;17:2494–502.PubMed
20.
Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastasis in patients with T1 esophageal adenocarcinoma. A retrospective review of esophagectomy specimens. Ann Surg. 2011;253:271–8.PubMed
21.
Merkow RP, Bilimoria KY, Keswani RN, et al. Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. J Natl Cancer Inst. 2014;106:dju133.PubMed
22.
Yamashina T, Ishihara R, Nagai K, et al. Long term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. Am J Gastroenterol. 2013;108:544–51.PubMed
23.
Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy. 2010;42:1030–6.PubMed
24.
Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008;15:3278–88.PubMed
25.
Yamada K, Murakami M, Okamoto Y, et al. Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma. Int J Rad Oncol Biol Phys. 2006;64:1106–11.
26.
Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–43.PubMed
27.
Shimizu Y, Kato M, Yamamoto J, et al. EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous–cell carcinoma. Gastrointest Endosc. 2004;59:199–204.PubMed
28.
Mayanagi S, Onitsuka T, Nakagawa M, et al. The use of short segment free jejunal transfer as salvage surgery for cervical esophageal and hypopharyngeal cancer. World J Surg. 2014;38:144–9.PubMed
29.
Ullah R, Bailie N, Kinsella J, et al. Pharyngo–laryngo–esophagectomy and gastric pull–up for post–cricoid and cervical oesophageal squamous cell carcinoma. J Laryngol Otol. 2002;116:826–30.PubMed
30.
Akutsu Y, Kato K, Igaki H, et al. The Prevalence of Overall and Initial Lymph Node Metastases in Clinical T1N0 Thoracic Esophageal Cancer: from the Results of JCOG0502, a Prospective Multicenter Study. Ann Surg. 2016;264:1009–15.PubMed
31.
Tachimori Y, Ozawa S, Numasaki H, et al. Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Efficacy of lymph node dissection by node zones according to tumor location for esophageal squamous cell carcinoma. Esophagus. 2016;13:1–7.PubMed
32.
Kataoka K, Takeuchi H, Mizusawa J, et al. Japan Esophageal Oncology Group/Japan Clinical Oncology Group. A randomized Phase III trial of thoracoscopic versus open esophagectomy for thoracic esophageal cancer: Japan Clinical Oncology Group Study JCOG1409. Jpn J Clin Oncol. 2016;46:174–7.PubMed
33.
Zehr KJ, Dawson PB, Yang SC, et al. Standardized clinical care pathways for major thoracic cases reduce hospital costs. Ann Thorac Surg. 1998;66:914–9.PubMed
34.
Low DE, Kunz S, Schembre D, et al. Esophagectomy—it’s not just about mortality anymore: standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer. J gastrointest Surg. 2007;11:1395–402.PubMed
35.
Munitiz V, Martinez-de-Haro LF, Ortiz A, et al. Effectiveness of a written clinical pathway for enhanced recovery after transthoracic (Ivor Lewis) oesophagectomy. Br J Surg. 2010;97:714–8.PubMed
36.
Fearon KC, Ljungqvist O, Von Meyenfeldt M, et al. Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colon resection. Clin Nutr. 2005;24:466–77.PubMed
37.
Findlay JM, Tustian E, Millo J, et al. The effect of formalizing enhanced recovery after esophagectomy with a protocol. Dis Esophagus. 2015;28:567–73.PubMed
38.
Findlay JM, Gillies RS, Millo J, et al. Enhanced recovery for esophagectomy: a systematic review and evidence–based guidelines. Ann Surg. 2014;259:413–31.PubMed
39.
Markar SR, Karthikesalingam A, Low DE. Enhanced recovery pathways lead to an improvement in postoperative outcomes following esophagectomy: systematic review and pooled analysis. Dis Esophagus. 2015;28:468–75.PubMed
40.
Shewale JB, Correa AM, Baker CM, et al. University of Texas MD Anderson Esophageal Cancer Collaborative Group: impact of a fast–track esophagectomy protocol on esophageal cancer patient outcomes and Hospital charges. Ann Surg. 2015;261:1114–23.PubMed
41.
Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5–fluorouracil (5–FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216–20.PubMed
42.
Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5–fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22:172–6.PubMed
43.
Kato K, Muro K, Ando N, et al. The Japan Esophageal Oncology Group of the Japan Clinical Oncology Group (JCOG). A phase II study of nedaplatin and 5–fluorouracil in metastatic squamous cell carcinoma of the esophagus: the Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905–DI). Esophagus. 2014;11:183–8.
44.
Honda M, Miura A, Izumi Y, et al. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Dis Esophagus. 2010;23:641–5.PubMed
45.
Hironaka S, Tsubosa Y, Mizusawa J, et al. Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Phase I/II trial of 2–weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci. 2014;105:1189–95.PubMedPubMedCentral
46.
Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single–agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.PubMed
47.
Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1–h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum–based chemotherapy. Cancer Chemother Pharmacol. 2011;67:1265–72.PubMed
48.
Jin J, Xu X, Wang F, et al. Second–line combination chemotherapy with docetaxel and nedaplatin for Cisplatin–pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol. 2009;4:1017–21.PubMed
49.
Dutton SJ, Ferry DR, Blazeby JM, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014;15:894–904.PubMed
50.
Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous–cell carcinoma: an open–label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631–9.PubMed
51.
Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.PubMed
52.
Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2006;1:CD002092.
53.
Nishimura Y, Ono K, Tsutsui K, et al. Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. Int J Radiat Oncol Biol Phys. 1994;30:1099–105.PubMed
54.
Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined–modality therapy for esophageal cancer: high–dose versus standard–dose radiation therapy. J Clin Oncol. 2002;20:1167–74.PubMed
55.
Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.PubMed
56.
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5–fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.PubMed
57.
Sjoquist KM, Burmeister BH, Smithers BM, et al. Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta–analysis. Lancet Oncol. 2011;12:681–92.PubMed
58.
van Hagen P, Hulshof MC, van Lanschot JJ, et al. CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.PubMed
59.
Nakamura K, Kato K, Igaki H, et al. Three–arm phase III trial comparing cisplatin plus 5–FU versus docetaxel, cisplatin plus 5–FU versus radiotherapy with CF (CF–RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT Study). Jpn J Clin Oncol. 2013;43:752–5.PubMed
60.
Motoori M, Yano M, Ishihara R, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol. 2012;19:2135–41.PubMed
61.
Igaki H, Kato H, Tachimori Y, et al. Clinicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinomas of the thoracic esophagus treated with three–field lymph node dissection. Eur J Cardiothorac Surg. 2001;20:1089–94.PubMed
62.
Kawaguchi G, Sasamoto R, Abe E, et al. The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer. Radiat Oncol. 2015;10:31.PubMedPubMedCentral
63.
Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425–33.PubMed
64.
Kato K, Muro K, Minashi K, et al. Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG). Phase II study of chemoradiotherapy with 5–fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Rad Onol Biol Phys. 2011;81:684–90.
65.
Kato K, Nakajima TE, Ito Y, et al. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II–III esophageal carcinoma. Jpn J Clin Oncol. 2013;43:608–15.PubMed
66.
Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.PubMed
67.
Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5–fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.PubMed
68.
Nishimura Y, Hiraoka M, Koike R, et al. Long–term follow–up of a randomized Phase II study of cisplatin/5–FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol. 2012;42:807–12.PubMed
69.
Shinoda M, Ando N, Kato K, et al. Randomized study of low–dose versus standard–dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106:407–12.PubMedPubMedCentral
70.
Higuchi K, Koizumi W, Tanabe S, et al. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5–fluorouracil (DCF–R) for advanced esophageal carcinoma: kitasato digestive disease & oncology group trial (KDOG 0501). Radiother Oncol. 2008;87:398–404.PubMed
71.
Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5–fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;155:1328–34.
72.
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01).Radiation Therapy Oncology Group. JAMA. 1999;281:1623–7.PubMed
73.
Wong RK, Malthaner RA, Zuraw L, et al. Cancer Care Ontario Practice Guidelines Initiative Gastrointestinal Cancer Disease Site Group. Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys. 2003;55:930–42.PubMed
74.
Nishimura Y, Koike R, Ogawa K, et al. Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey. Int J Clin Oncol. 2012;17:48–54.PubMed
75.
Umezawa R, Jingu K, Matsushita H, et al. Long–term results of chemoradiotherapy for stage II–III thoracic esophageal cancer in a single institution after 2000–with a focus on comparison of three protocols. BMC Cancer. 2015;15:813.PubMedPubMedCentral
76.
Ishikura S, Nihei K, Ohtsu A, et al. Long–term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:2697–702.PubMed
77.
Morota M, Gomi K, Kozuka T, et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2009;75:122–8.PubMed
78.
Asakura H, Hashimoto T, Zenda S, et al. Analysis of dose–volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. Radiother Oncol. 2010;95:240–4.PubMed
79.
Tachimori Y, Kanamori N, Uemura N, et al. Salvage esophagectomy after high–dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovas Surg. 2009;137:49–54.
80.
Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175–83.PubMed
81.
Meunier B, Raoul J, Le Prisé E, et al. Salvage esophagectomy after unsuccessful curative chemoradiotherapy for squamous cell cancer of the esophagus. Dig Surg. 1998;15:224–6.PubMed
82.
Nakamura T, Hayashi K, Ota M, et al. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg. 2004;188:261–6.PubMed
83.
Takeuchi H, Saikawa Y, Oyama T, et al. Factors influencing the long–term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg. 2010;34:277–84.PubMed
84.
Yano T, Muto M, Hattori S, et al. Long–term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. 2008;40:717–21.PubMed
85.
Makazu M, Kato K, Takisawa H, et al. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer. Dis Esophagus. 2014;27:42–9.PubMed
86.
Hatogai K, Yano T, Kojima T, et al. Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer. Radiat Oncol. 2016;11:31.PubMedPubMedCentral
87.
Katada C, Muto M, Manabe T, et al. Local recurrence of squamous–cell carcinoma of the esophagus after EMR. Gastrointest Endosc. 2005;61:219–25.PubMed
88.
Esaki M, Matsumoto T, Hirakawa K, et al. Risk factors for local recurrence of superficial esophageal cancer after treatment by endoscopic mucosal resection. Endoscopy. 2007;39:41–5.PubMed
89.
Toyonaga T, Man-i M, East JE, et al. 1,635 Endoscopic submucosal dissection cases in the esophagus, stomach, and colorectum: complication rates and long–term outcomes. Surg Endosc. 2013;27:1000–8.PubMed
90.
Urabe Y, Hiyama T, Tanaka S, et al. Metachronous multiple esophageal squamous cell carcinomas and Lugol–voiding lesions after endoscopic mucosal resection. Endoscopy. 2009;41:304–9.PubMed
91.
Ono S, Fujishiro M, Niimi K, et al. Long–term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc. 2009;70:860–6.PubMed
92.
Katada C, Muto M, Tanabe S, et al. Surveillance after endoscopic mucosal resection or endoscopic submucosal dissection for esophageal squamous cell carcinoma. Dig Endosc. 2013;25(Suppl 1):39–43.PubMed
93.
Toh Y, Oki E, Minami K, et al. Follow–up and recurrence after a curative esophagectomy for patients with esophageal cancer: the first indicators for recurrence and their prognostic values. Esophagus. 2010;7:37–43.
94.
Kunisaki C, Makino H, Takagawa R, et al. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg. 2008;12:802–10.PubMed
95.
Sugiyama M, Morita M, Yoshida R, et al. Patterns and time of recurrence after complete resection of esophageal cancer. Surg Today. 2012;42:752–8.PubMed
96.
Toh Y, Kitagawa Y, Kuwano H, et al. A nation–wide survey of follow–up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan. Esophagus. 2016;13:173–81.
97.
Chuang SC, Hashibe M, Scelo G, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev. 2008;17:1543–9.PubMed
98.
Morita M, Saeki H, Ito S, et al. Surgical strategies for esophageal cancer associated with head and neck cancer. Surg Today. 2014;44:1603–10.PubMed
99.
Hori K, Okada H, Kawahara Y, et al. Lugol–voiding lesions are an important risk factor for a second primary squamous cell carcinoma in patients with esophageal cancer or head and neck cancer. Am J Gastroenterol. 2011;106:858–66.PubMed
100.
Katada C, Tanabe S, Koizumi W, et al. Narrow band imaging for detecting superficial squamous cell carcinoma of the head and neck in patients with esophageal squamous cell carcinoma. Endoscopy. 2010;42:185–90.PubMed
101.
Miyata H, Yamasaki M, Kurokawa Y, et al. Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. Ann Surg Oncol. 2011;18:3353–61.PubMed
102.
Kato H, Fukuchi M, Miyazaki T, et al. Classification of recurrent esophageal cancer after radical esophagectomy with two– or three–field lymphadenectomy. Anticancer Res. 2005;25:3461–8.PubMed
103.
Abate E, DeMeester SR, Zehetner J, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow–up intervals and testing. J Am Coll Surg. 2010;210:428–35.PubMed
104.
Jingu K, Nemoto K, Matsushita H, et al. Results of radiation therapy combined with nedaplatin (cis–diammine–glycoplatinum) and 5–fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer. 2006;6:50.PubMedPubMedCentral
105.
Watanabe M, Mine S, Yamada K, et al. Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus. Gen Thorac Cardiovasc Surg. 2014;62:685–92.PubMed
106.
Watanabe M, Nishida K, Kimura Y, et al. Salvage lymphadenectomy for cervical lymph node recurrence after esophagectomy for squamous cell carcinoma of the thoracic esophagus. Dis Esophagus. 2012;25:62–6.PubMed
107.
Nakamura T, Ota M, Narumiya K, et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008;15:2451–7.PubMed
108.
Tsuchida E, Sakai K, Matsumoto Y, et al. Concurrent chemoradiotherapy using low–dose continuous infusion of 5–fluorouracil for postoperative regional lymph node recurrence of esophageal squamous cell carcinoma. Esophagus. 2005;2:25–31.
109.
Zhu YL, Li Q, Gao JM, et al. A retrospective evaluation of radiotherapy for the treatment of local esophageal squamous cell carcinoma recurrence after initial complete surgical resection. J Investig Med. 2013;61:34–9.PubMed
110.
Baxi SH, Burmeister B, Harvey JA, et al. Salvage definitive chemo–radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review. J Med Imaging Radiat Oncol. 2008;52:583–7.PubMed
111.
Shioyama Y, Nakamura K, Ohga S, et al. Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Jpn J Clin Oncol. 2007;37:918–23.PubMed
112.
Yamashita H, Nakagawa K, Tago M, et al. Salvage radiotherapy for postoperative loco–regional recurrence of esophageal cancer. Dis Esophagus. 2005;18:215–20.PubMed
113.
Ichida H, Imamura H, Yoshimoto J, et al. Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma. World J Surg. 2013;37:398–407.PubMed
114.
Wang S, Tachimori Y, Hokamura N, et al. Prognostic analysis of salvage esophagectomy after definitive chemoradiotherapy for esophageal squamous cell carcinoma: the importance of lymphadenectomy. J Thorac Cardiovasc Surg. 2014;147:1805–11.PubMed
115.
Chen Y, Lu Y, Wang Y, et al. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. Dis Esophagus. 2014;27:134–40.PubMed
116.
Takeuchi M, Kobayashi M, Hashimoto S, et al. Salvage endoscopic submucosal dissection in patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Scand J Gastroenterol. 2013;48:1095–101.PubMed
117.
Matono S, Fujita H, Tanaka T, et al. Salvage lymphadenectomy without esophagectomy is an option for recurrent or residual lymph nodes after definitive chemoradiotherapy for esophageal cancer. Esophagus. 2014;11:197–203.
118.
Freeman RK, Ascioti AJ, Mahidhara RJ. Palliative therapy for patients with unresectable esophageal carcinoma. Surg Clin North Am. 2012;92:1337–51.PubMed
119.
Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer—an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230–44.PubMed
120.
Amdal CD, Jacobsen AB, Guren MG, et al. Patient–reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review. Acta Oncol. 2013;52:679–90.PubMed
121.
Dai Y, Li C, Xie Y, et al. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev. 2014;10:5048.
122.
Hürtgen M, Herber SC. Treatment of malignant tracheoesophageal fistula. Thorac Surg Clin. 2014;24:117–27.PubMed
123.
Margolis M, Alexander P, Trachiotis GD, et al. Percutaneous endoscopic gastrostomy before multimodality therapy in patients with esophageal cancer. Ann Thorac Surg. 2003;76:1694–7.PubMed
124.
Naef AP, Savary M, Ozzello L. Columnar–lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett’s esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg. 1975;70:826–35.PubMed
125.
Armstrong D. Review article: towards consistency in the endoscopic diagnosis of Barrett’s oesophagus and columnar metaplasia. Aliment Pharmacol Ther. 2004;20(5):40–7 (discussion 61–2).PubMed
126.
Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C and M criteria. Gastroenterology. 2006;131:1392–9.PubMed
127.
Spechler SJ, Fitzgerald RC, Prasad GA, et al. History, molecular mechanisms, and endoscopic treatment of Barrett’s esophagus. Gastroenterology. 2010;138:854–69.PubMed
128.
Takubo K, Vieth M, Aida J, et al. Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett’s adenocarcinoma, the definition of Barrett’s esophagus, and histologic criteria for mucosal adenocarcinoma or high–grade dysplasia. Digestion. 2009;80:248–57.PubMed
129.
Riddell RH, Odze RD. Definition of Barrett’s esophagus: time for a rethink—is intestinal metaplasia dead? Am J Gastroenterol. 2009;104:2588–94.PubMed
Metadata
Title
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
Authors
Yuko Kitagawa
Takashi Uno
Tsuneo Oyama
Ken Kato
Hiroyuki Kato
Hirofumi Kawakubo
Osamu Kawamura
Motoyasu Kusano
Hiroyuki Kuwano
Hiroya Takeuchi
Yasushi Toh
Yuichiro Doki
Yoshio Naomoto
Kenji Nemoto
Eisuke Booka
Hisahiro Matsubara
Tatsuya Miyazaki
Manabu Muto
Akio Yanagisawa
Masahiro Yoshida
Publication date
01-01-2019
Publisher
Springer Nature Singapore
Published in
Esophagus / Issue 1/2019
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-018-0642-8

Other articles of this Issue 1/2019

Esophagus 1/2019 Go to the issue

Special Article

Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1

Original Article

Perioperative enteral supplementation with glutamine, fiber, and oligosaccharide reduces early postoperative surgical stress following esophagectomy for esophageal cancer

Original Article

A new esophageal elongation technique for long-gap esophageal atresia: in vitro comparison of myotomy techniques

Original Article

Comparison of esophageal submucosal glands in experimental models for esophagus tissue engineering applications

Original Article

Survival benefit of multimodal local therapy for repeat recurrence of thoracic esophageal squamous cell carcinoma after esophagectomy

Original Article

Robot-assisted mediastinoscopic esophagectomy for esophageal cancer: the first clinical series
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits